Market Outlook- 11 June 2021

The Nikkei index in ended the day higher Prime Minister Yoshihide Suga said during a on Thursday, with shipping companies rising on debate between party leaders on Wednesday that the likelihood of additional economic reopenings Japan expects to finish vaccination all residents and drugmakers benefiting from reports of who have applied for shots by October-November. government backing. Eisai fell 7.02 percent by daily limit following two Following favourable overnight indications from days of advances. US regulators authorised a Wall Street, the Japanese stock market is medication developed by the company and marginally higher in choppy trading on Friday, for Alzheimer's disease earlier this week. So far extending the small gains of the previous this week, the stock has increased by 30%. sessions, with the benchmark barely below the 29,000 mark. , a competitor, jumped 3.4 percent after local media reported that the company aims to 225 index rose 0.34 percent to mass-produce its own COVID-19 vaccinations. 28,958.56, while the broader Topix index fell 0.02 percent to 1,956.73. On a media report that they will receive government funding for their research on COVID- The TSE's air transport index reached a 15-month high before falling 0.49 percent as profit-taking 19 medications, Chugai Pharmaceutical gained investors took profits. 1.04 percent and gained 1.5 percent.

Top Gainers Top Losers

Company Last Price Change% Company Last Price Change%

Eisai Co. Ltd. 7.00% ¥ 10,700 Corp. ¥ 2,266 -4.99% Japan Post Holdings ¥ 932 2.89% Co. Ltd. Motors Ltd. ¥ 1,521 -3.86% BANDAI NAMCO ¥ 8,282 3.24% Holdings Inc. Motor Corp. ¥ 987 -3.52% Co. ¥ 2,568 2.82% Ltd. T&D Holdings Inc. ¥ 1,423 -3.20% Chugai Kawasaki Heavy Pharmaceutical Co. ¥ 4,365 2.30% ¥ 2,454 -3.20% Ltd. Industries Ltd. Market Outlook- 11 June 2021

Disclaimer and General Advice Instructions:

This document is provided by Laverne Securities Pty Ltd T/as La Verne Investing the Corporate Authorized Representative No. CAR No. 001269781 of La Verne Capital Pty Ltd AFSL 482937. The Research Analyst who prepared this report/article hereby certifies that the views expressed in this document accurately reflect the analyst’s personal views about the Company and its financial products. The information provided in the Report/Article is provided by Morningstar and FactSet. La Verne Fund is not a fund manager, however, the portfolio and the document is for general advice only, prepared by the Analysts and Research team for our clients.

This report/article have Different Assumptions, Views, Analytical Method of the analyst with no guarantee of reliability and accuracy of the content. The Research Analyst has not been, is not, and will not be receiving direct or indirect compensation for expressing the specific recommendations or views in this report/article. La Verne Securities has its own Research methodology, with regards to the rating and is confirmed by the team for long term Strategic rating of the concerned security as an Investment for Portfolios with High Growth High Risk Profile. Individual Stock is Speculative and of High Risk in nature and strongly

This Document is provided for the Advisors, their Clients, and Financial Professionals for information only and should not be considered an offer or solicitation of an offer to buy or sell a particular security or financial product or instrument.

The information or services provided in this report/article may not be suitable for you and we strongly recommend taking the advice of your Financial Planner or Investment advisors. Laverne Investing will not treat the recipients as its customer by virtue of their receiving the report/article and should seek the advice of their consultant, prior to making any investment decision considering this report/article